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ABSTRACT 
White adipose tissue (WAT) is a highly plastic organ which secretes a large number of 
peptide factors termed adipokines. Increased caloric intake increases WAT mass which 
results in marked alterations in the secretory pattern. This may be mediated via both 
transcriptional and post-transcriptional mechanisms. Obesity is associated with several 
complications including type 2 diabetes mellitus (T2DM), hypertension, cardiovascular 
disease and cancer. The overall aim of this thesis was to identify microRNAs (miRNA) in 
obese WAT and to determine if they regulate genes, in particular those encoding adipokines 
that are linked to obesity-associated insulin resistance.  
In Study I, we investigated miRNA regulation of Chemokine (C-C Motif) Ligand 2 (CCL2) 
by extending and validating a recently identified transcriptional regulatory network in human 
adipocytes. The updated subnetwork predicted that miR-126-3p, miR-193b-3p and miR-92a-
3p control CCL2 production through several transcription factors (TFs) such as v-ets 
erythroblastosis virus E26 oncogene homolog 1 (avian) (ETS1), MYC-associated factor X 
(MAX), and specificity protein 1 (SP1). Selective down-regulation of ETS1, MAX, or SP1 in 
human adipocytes attenuated CCL2 production and a concomitant gene silencing of ETS1 
and MAX resulted in an additive reduction in CCL2 production. Overexpression of miR-126-
3p, miR-193b-3p and miR-92a-3p in various pairwise combinations reduced CCL2 secretion 
in an additive manner although the effects of different miRNA combinations were cell-
specific in adipocytes and macrophages. These findings add novel insights into the TF and 
miRNA-mediated regulation of CCL2 production in human adipocytes.  
In Study II, we identified adipocyte-expressed miRNAs altered by obesity that regulate 
adiponectin production. We found that miR-193b-3p increased adiponectin secretion and 
mRNA expression when overexpressed in human adipocytes. The expression of miR-193b-
3p significantly correlated with adiponectin gene expression and insulin resistance measured 
by homeostasis model assessment of insulin resistance. We identified that miR-193b-3p binds 
directly to the 3'-UTR of negative adiponectin regulators such as nuclear transcription factor 
Y α and nuclear receptor interacting protein 1. This explains how miR-193-3p impacts 
adiponectin expression and secretion.  
A WAT phenotype characterized by few but large fat cells (hypertrophy) is linked to 
metabolic complications. In Study III, we identified miRNAs that were significantly 
upregulated in hypertrophic WAT. Out of 15 identified miRNA, 10 were predicted to bind to 
early B cell factor 1 (EBF1), a recently described regulator of WAT morphology.  Two 
miRNAs (miR-361-3p and miR-574-3p) bound directly to the 3'-UTR of EBF1 and reduced 
EBF1 expression alone as well as in a combinatorial manner. Transcription activity of EBF1 
was negatively correlated with the expression of the miRNAs.  
In Study IV, we identified 11 miRNAs that were differentially expressed between insulin 
sensitive and insulin resistance obese individuals. MiR-143-3p and miR-652-3p affected 
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insulin-stimulated glucose uptake either directly or indirectly affecting several insulin 
signaling regulators including Ectonucleotide pyrophosphatase/phosphodiesterase 1 
(ENPP1), Protein Kinase, AMP-activated, Alpha 2 Catalytic Subunit (PRKAA2) as well as 
posttranslational phosphorylation of AKT2, AMP-activated protein kinase and insulin 
receptor substrate 1. Expression levels of miR-143-3p and miR-652-3p correlated 
significantly with insulin-stimulated lipogenesis suggesting that the levels of these miRNAs 
may also be of clinical importance.  
In summary, we have defined the regulatory pathways for several miRNAs that are 
dysregulated in obese WAT and that may have a pathophysiological impact. Our studies 
describe the involvement of miRNAs in regulating the expression of CCL2, adiponectin, 
EBF1, ENPP1 and PRKAA2. These results provide a better understanding of the role of 
miRNAs in the regulation of WAT function in health and disease.  
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1 INTRODUCTION                                                                                           
1.1 OBESITY 
Obesity prevalence has grown rapidly in the last decades and is a worldwide health and 
society problem (1). In 2014, the estimated number of overweight and obese adults was more 
than 1.9 billion, of which 600 million fulfilled the WHO criteria for obesity (2). Initially, this 
was mainly a concern in high-income countries however now it also poses a problem to 
middle and low-income countries. Obesity belongs to the cluster of medical conditions 
termed metabolic syndrome which is defined by visceral adiposity, hypertension, 
dyslipidemia and high blood pressure (3). The metabolic syndrome is associated with a 
number of complications such as type 2 diabetes (T2D), cardiovascular disease and cancer to 
mention a few (3). Since the 1980s, the prevalence of T2D has risen from 108 to 422 
million in 2014 which parallels the increase in obesity (4).  This constitutes a large financial 
burden to society and so far the counter-measures have been insufficient (5,6).  
From an evolutionary perspective the human body is set to conserve calories in order to 
withstand periods of limited food supply. Our modern society provides almost unlimited 
availability to calorically dense foods and leads a sedentary lifestyle. According to the thrifty 
gene hypothesis, it is our evolutionary conserved genome that explains the resulting increase 
in obesity prevalence (7,8). In simple terms, development of obesity is primarily explained by 
an imbalance between energy-intake and energy expenditure. Early onset development of 
obesity e.g. during childhood increases the risk to become overweight or obese in adult life. 
Low economic status and education level are additional risk factors (9). Contrary to common 
belief, genetic mutations in selected genes do not contribute to common forms of obesity 
(10).  
Obesity can be defined in numerous ways such as body mass index (BMI), waist 
circumference, waist/hip circumference ratio (WHR) and body fat percentage. The most 
frequently used method in research is BMI due to applicability in large-scale epidemiological 
studies; it is quickly measured and relatively reproducible. BMI is calculated by dividing the 
individual’s weight in kilogram with the square of their height in meters (kg/m2). The 
categories reflects weight related problems; the division of classes are shown in Table 1 (11). 
One should mention that BMI scaling is applied for white Caucasian adults and does not 
include elderly, children or well-trained individuals. BMI classification is also arbitrary for 
other ethnic groups, especially for Asian populations  thus highlighting the need to develop a 
more suitable classification system for other ethnic groups (12). Waist circumference is a 
better indicator for abdominal fat accumulation and risk predictor of obesity-related 
morbidities.  The cut-off values for increased relative risk of disease is <102 cm for men and 
<88 cm for women (11). A more accurate assessment of body fat requires more advanced 
equipment or time than BMI and WHR. It requires a specialist, thus cannot be self-assessed, 
performing measurements such as skin fold thickness, bioelectric impedance, air/water 
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displacement, whole body dual energy X-ray absorptiometry (DEXA) and computerized 
tomography and magnetic resonance imaging.  
Table 1. BMI categories 
 
Categories 
 
BMI (kg/m
2
) 
Underweight  >18.5 
Normal weight 18.5-24.9 
Overweight 25.0-29.9 
Obese  <30.0 
 
Weight reduction can only be achieved by altering the equilibrium between energy-intake and 
energy expenditure. However, calorie restriction and exercise is very demanding for the 
individual and  hard to maintain (6). To date, the best method for weight reduction is bariatric 
surgery. There are several techniques such as gastric bypass, gastric sleeve and gastric 
banding. Gastric banding results in less pronounced weight reduction and has therefore 
become less used (13). Gastric bypass rapidly improves the metabolic profile and glucose 
control, even prior to weight loss. This is achieved via an altered hormonal release in 
response to food intake, e.g. increased levels of glucagon like peptide -1 and peptide YY but 
reduced ghrelin levels. Altogether these changes increase insulin release and the sense of 
satiety (14). However the main disadvantage of bariatric surgery is the highly expensive costs 
and is therefore not a sustainable solution for treating obesity.  
1.2 ADIPOSE TISSUE AND ITS FUNCTIONS 
In terms of size, white adipose tissue (WAT) displays the most pronounced inter-individual 
variations. In extreme states, humans may have fat ranging from a few percent up to 50 % of 
the total body weight. WAT is a loose connective tissue where almost all volume is 
consisting of adipocytes. Adipocytes are surrounded by the stromal vascular fraction (SVF), 
which is composed of progenitor cells, fibroblasts, leucocytes and endothelial cells. WAT in 
humans can be divided into two main compartmental sites, visceral and subcutaneous. 
Visceral fat is located in the abdominal cavity and is known to be more metabolically active. 
This region releases non-esterified fatty acids (NEFAs) directly into the portal vein that 
transports blood to the liver and pancreas, two organs sensitive to lipotoxicity. Subcutaneous 
fat is located underneath the skin and serves as thermal isolation and a mechanical shield for 
the body. However, its most important function is to store and release energy. Excess energy 
is accumulated in the form of triacylglycerides (TAG). During energy deficiency TAGs are 
hydrolyzed into NEFAs and glycerol, a process termed lipolysis (detailed in section 1.2.1.1). 
Last but not least, WAT also serves as an endocrine organ, secreting a large number of 
factors and proteins named adipokines (detailed in section 1.5). 
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1.2.1 Adipocytes 
Adipocytes have a large lipid droplet that constitutes >95% of the cell volume. In WAT, 
adipocytes constitute at least 90 % of the tissue volume and about 10 % of the adipocytes are 
renewed every year (15). Adipocytes are recognized as critical regulators of whole-body 
metabolism primarily through lipolysis and NEFA synthesis (lipogenesis), in the following 
section a more comprehensive description will be given.  
1.2.1.1 Lipolysis 
Lipolysis is the enzymatic breakdown of TAGs. One TAG is broken down to one glycerol 
molecule and three NEFA molecules and this is achieved in three steps: 
I. TAG is hydrolyzed to diacylglycerol (DAG) by adipose triglyceride lipase (ATGL) 
II. DAG is converted to monoacylglycerol (MAG) by hormone sensitive lipase (HSL) 
III. The breakdown of MAG to NEFAs and glycerol is accomplished by both 
monoacylglycerol lipase (MGL) and HSL. 
ATGL is the rate-limiting enzyme of lipolysis. A small part of NEFAs remain in the 
adipocyte for re-esterification but first NEFAs are activated by the addition of coenzyme A 
(CoA). Most of the NEFAs are released into the circulation bound to albumin and can be 
used through β-oxidation by other organs such as muscles, the pancreas, heart and liver to 
produce energy. In the liver, NEFAs are also used for synthesis of TAG or very low-density 
lipoprotein (VLDL). The phosphorylation of the glycerol molecule generated in adipocytes 
does not occur due to the low expression of the enzyme glycerol-3-kinase. Although it is 
phosphorylated to glycerol 3-phosphate in the liver where it can further be used for 
lipogenesis (16).  
Lipolysis occurs constantly at a low rate which is termed basal (spontaneous) lipolysis. 
Lipolysis is regulated by numerous factors but in humans the most essential are 
catecholamine’s, natriuretic peptides (both pro-lipolytic) and insulin (anti-lipolytic). The 
effects of catecholamine’s are somewhat complex as they induce lipolysis through β 
adrenergic receptors and inhibit it via α2-A adrenergic receptor (16). Tumor necrosis factor α 
(TNF-α) also belong to the more important lipolysis regulators (16). Other factors that also 
impact lipolysis are age, gender, nutrition and physical activity. Lipolysis is altered in 
different metabolic conditions; in obesity basal lipolysis is increased whereas stimulated 
lipolysis is attenuated. The end result is elevated circulating levels of NEFAs which are 
normalized upon weight reduction.  
1.2.1.2 Lipogenesis  
Liver is the primary tissue for de novo lipogenesis, synthesis of NEFA (17). This pathway is 
mainly stimulated by elevated glucose and insulin concentration in the blood and 
consequently augmented glucose uptake in hepatocytes. Intracellularly, glucose is 
phosphorylated to glucose-6-phosphate and processed further to acetyl-CoA, which is an 
important intermediate substrate for NEFA production. Glucose uptake by WAT is minor in 
 12 
comparison to whole body uptake, constituting approximately 5 – 10 % (18). Instead the 
main source for WAT lipogenesis originates from diet fat for synthesis of TAG. In the blood 
TAGs are transported in lipoproteins such as chylomicrons or VLDL. On the cell membrane 
of adipocytes, lipoprotein lipases attach to VLDL and cleave TAGs into NEFAs thereby 
allowing the adipocyte to take up NEFAs through fatty acid transporter or passive diffusion. 
Once inside the cell, the enzyme fatty acyl-CoA synthetase catalyzes the formation of fatty 
acyl-CoA by addition of CoA to NEFAs. The formation of TAGs can now occur; three 
NEFAs are assembled with one glycerol 3-phosphate. The uptake of glucose and TAGs from 
VLDL is highly dependent on insulin. In obesity, the insulin response is reduced meaning 
that the storage of fat is attenuated. This results in ectopic storage of fat in non-adipose tissues 
causing lipotoxic effects. 
1.3 ENDOCRINE FUNCTION OF ADIPOSE TISSUE 
1.3.1 Insulin  
Insulin is the most important hormone for regulating energy homeostasis and its most 
prominent effect on glucose metabolism are exerted on the muscle, liver and WAT (18). In 
WAT insulin has a central role in inhibiting lipolysis and stimulating processes such as 
adipocyte differentiation, lipogenesis, glucose and NEFA uptake as well as NEFA re-
esterification.  
1.3.1.1 Insulin signaling 
Insulin is controlled at numerous levels and more than 100 genes are involved in the 
regulation as well as numerous phosphorylation events (19,20). There are two insulin-
signaling pathways: 
1. Phosphatidylinositol-3 kinase (PI3K) dependent pathway  
2. Non-canonical CBL-TC10 pathway 
The insulin signaling cascades are initiated when insulin binds to the insulin receptor 
extracellularly subsequently activating intracellular auto-phosphorylation of tyrosine 
residues. The phosphorylated  parts acts as docking sites for insulin receptor substrate (IRS) 
proteins leading to the tyrosine phosphorylation of IRS.  The IRS proteins stimulate PI3K 
which catalyzes the conversion of phosphatidylinositol-4, 5-diphosphate (PIP2) to 
phosphatidylinositol-3, 4, 5-trisphosphate (PIP3). The membrane-bound PIP3 binds and 
activates phosphoinositide dependent protein kinase 1 (PDPK1).  In turn, PDPK1 together 
with mammalian target of rapamycin complex 2, phosphorylates AKT at different sites thus 
activating it. The activation of AKT is central for glucose uptake and regulation of 
lipolysis. For glucose uptake, AKT catalyzes phosphorylation of AKT substrate 160 
(AS160). Phosphorylated AS160 is inactivated thereby allowing the increased translocation 
of GLUT4-containing vesicles to the membrane and facilitating glucose uptake. The activated 
AKT will mediate inhibitory effect on lipolysis by phosphorylation of phosphodiesterase 3B 
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(PDE3B). PDE3B ameliorates degradation of cAMP to 5’AMP that decreases 
phosphorylation events of PKA and HSL, thus their activity.  
Within the CBL-TC10 pathway, insulin receptor binds to the proteins APS, C-cbl 
associated protein and CBL followed by phosphorylation.  Activated CBL triggers docking 
of CRK guanine nucleotide exchange factor, C3G, to the plasma membrane, which further 
stimulates small GTPase TC10 and GLUT4 translocation. Numerous genes and 
phosphorylation events control the recycling process of GLUT4. Detailed description of the 
signaling events linked to GLUT4 have been extensively reviewed (19).  
1.3.1.2 Insulin resistance 
Insulin resistance (IR) is a pathological condition where cells display a reduced ability to 
respond to insulin. This results in augmented glucose levels in the blood and is compensated 
by increased production of insulin from the pancreas. With time, the β-cells in the pancreas 
will lose their ability to produce insulin in sufficient amounts and the peripheral tissues 
gradually increase IR. Glucose levels therefore increase, leading to hyperglycemia and the 
development of T2D. IR occurs in several organs but the complete mechanistic pathology is 
not fully understood. From a WAT perspective, the increased lipolysis in obesity augments 
NEFA levels in the blood with deleterious effects by promoting lipid storage in muscle, liver 
and pancreas (21). In muscle, NEFAs will impair glucose uptake by activation of protein 
kinase C (PKC) , which will prevent insulin to stimulate muscle glucose uptake by reducing 
the intracellular GLUT4 translocation. NEFAs also reduce hepatic insulin signaling through 
their activation of PKCε. The activated kinase will also limit insulin-stimulated glycogen 
synthesis but the lipid synthesis remains constant. In addition, by increasing the hepatic levels 
of acetyl-CoA, NEFAs will activate hepatic gluconeogenesis causing increased release of 
glucose into the circulation (18).  
1.3.2 Adipokines  
It is well established that WAT is an endocrine organ, secreting a large number of factors 
termed adipokines. These are released to the bloodstream and affect processes linked to 
glucose and fat metabolism in muscle, liver and brain. Adipokines also have an important 
function for the communication between the various cell types within the tissue, interacting in 
an auto-paracrine fashion. The cross talk is essential for the regulation of processes such as 
adipogenesis, proliferation, vascularization, inflammation, stress, metabolism and tissue 
structure (22). Due to the great numbers of adipokines, only the most relevant for this thesis 
will be described in the following section. 
1.3.2.1 Adiponectin 
Adiponectin was first discovered two decades ago and since then it has been intensively 
studied (23). Adiponectin is a unique adipokine because of its anti-inflammatory effects. In 
obesity, plasma levels of adiponectin are markedly reduced compared to lean individuals 
(24). Adiponectin consists of 244 amino acids; the monomeric form is 28 kDa. In the 
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circulation adiponectin is only found in three isoforms where the monomer is associated to 
structures linked with disulphide bonds:  
I. Trimers, low-molecular weight (LMW), 67 kDa 
II. Hexamer, medium molecular weight (MMW), >120 kDa 
III. Higher order multimers, high molecular weight (HMW), > 300kDa 
The oligomeric isoforms are not equally potent, though, HMWs are believed to be the most 
active form exerting the insulin-sensitizing effects (25,26). In addition, there are several post-
translational modifications that contribute to diverse multimerization and function (27). A 
central step for these biological effects is mediated through phosphorylation of AMP-
activated protein kinase (AMPK) (28,29). This step is facilitated by another protein linking 
the ligand and the ADIPOR1/2 receptor, adaptor Protein, Phosphotyrosine Interaction, PH 
Domain And Leucine Zipper Containing 1 (APPL1) (30). Adiponectin mediates its effects by 
binding to two receptors, ADIPOR1 and ADIPOR2, which are expressed in muscle and liver. 
In muscle, adiponectin enhances NEFA oxidation as well as glucose transport by promoting 
translocation of GLUT4 (28). In the liver, adiponectin decreases gluconeogenesis and 
improves insulin sensitivity (31). Consequently, mice lacking adiponectin develop IR (32).  
1.3.2.2 Chemokine (C-C motif) ligand 2  
Chemokine (C-C Motif) Ligand 2 (CCL2) also called monocyte chemotactic protein 1 was 
initially identified as a chemokine secreted by macrophages as well as endothelial cells, and 
is a key factor for the recruitment of monocytes from the circulation. Once in the tissue, 
monocytes will differentiate into macrophages by activation from various actors e.g. 
lipopolysaccharides, interferon γ and interleukin 6 (IL-6). Murine models have revealed that 
CCL2 is also secreted from adipocytes and is an important player in the inflammatory 
response due to its chemoattractant action on macrophages in obese WAT. When CCL2 is 
disrupted in mice on a high fat diet, they get resilient to obesity-induced IR and display 
features such as improved insulin sensitivity, increased macrophage response and decreased 
hepatic TAG content (33). Similar results are obtained when knocking down the CCL2 
receptor; C-C motif chemokine receptor-2 (34). 
There are also indications that this cytokine may contribute to the pathogenesis of IR by 
disrupting glucose uptake. This was demonstrated in 3T3-L1 murine cells treated with CCL2 
where glucose uptake was significantly impaired (35). Other cells within WAT may also 
contribute to the production of CCL2, in fact the secretion is significantly larger from SVF 
compared to isolated adipocytes (36). In obese humans, visceral fat have a significantly 
higher production of CCL2 compared to subcutaneous fat but when adjusting for the number 
of macrophages the difference is attenuated (36). Altogether, evidence indicates that CCL2 is 
involved in obesity-related disorders such as adipose tissue inflammation and might be a link 
to IR. 
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1.4 PATHOGENSIS MECHANISMS OF ALTERED WAT IN OBESITY 
WAT is a highly plastic organ with large variations in size and the adipose tissue remodeling 
is an ongoing process that is accelerated in obesity. This is characterized by functional 
dysregulation of WAT, such as altered release of adipokines and NEFAs. There are several 
different pathways involved in these changes such as increased inflammation and immune 
cell infiltration, reduced vascularization, increased extra cellular matrix (ECM) production 
and altered morphology of WAT. The chronological order of the mentioned events are 
debated but altogether increase the risk for obesity-associated complications (37).  
1.4.1 Inflammation 
Adipose tissue contains a distinct population of immune response cells, macrophages and 
lymphocytes. In obesity, there is an increased infiltration of macrophages, which are 
important regulators of WAT inflammation. The chronic low-grade inflammation in WAT is 
suggested to link increased adiposity to reduced insulin sensitivity by attracting more pro-
inflammatory cells. Consequently, there will be increased levels of cytokines such as TNF-α 
and IL-6, both inducing lipolysis in adipocytes. CCL2 is also induced, and acts as an 
important chemoattractant factor in WAT, as described previously in section 1.3.2.2. 
Adipose tissue macrophages (ATMs) are essential for the dynamic state of adipose tissue, 
allowing it to adjust to changes in energy expenditure and intake by increasing or reducing fat 
mass. ATMs are classified into two main phenotypes “M2” and “M1”. The role of M2 ATMs 
is to clear the tissue from lipids, cellular debris and apoptotic cells (37) and to preserve a 
normal function of adipocyte. In contrast, M1 ATMs are overrepresented in the obese state 
and are characterized by increased release of cytokines (TNF-α, IL-6 and CCL2).  In severe 
obesity, M1 macrophages aggregate around necrotic adipocytes forming crown-like structure 
which reflects an inflammatory state (22,37). Recently, the dichotomous categorization into 
M1 and M2 has been suggested to be oversimplified as the phenotypic range of ATMs 
appears to be considerably more complicated (38).  
1.4.2 Morphology  
The morphology of WAT, i.e. the size and number of fat cells, is an important aspect of 
obesity, related to dysfunction and fat cell metabolism. At any given amount of fat mass, the 
tissue can be composed of few large fat cells (hypertrophy) or numerous small cells 
(hyperplasia) (39). This hypothesis was first coined in the sixties but it has subsequently been 
shown that hyperplasia is more beneficial from a metabolic point of view whereas 
hypertrophy is associated with increased adipose inflammation, lipolysis, IR and risk of type 
2 diabetes (40,41). The mechanisms that promote the development of these opposing 
phenotypes are not clear.  
1.4.2.1  Early B cell factor 1 as a regulator for adipocyte morphology 
The transcription factor Early B cell factor 1 (EBF1) has been recently demonstrated as an 
important factor regulating WAT morphology (42). EBF1 was originally identified as an 
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essential player for B-lymphocytes maturation (43).  Later it was shown to be involved in the 
development of other cell types including adipocytes (44). In adipogenesis, EBF1 is 
participates in the early adipocyte commitment and has shown to bind to peroxisome 
proliferator-activated receptor γ (PPARγ) and CCAAT-enhancer-binding protein α (C/EBPα) 
(45). In EBF1 knock out mice, there is a pronounced difference in size of the mice. EBF1 
deficient mice are significantly smaller and display an increase in bone formation and 
reduced adipose tissue  (46). In recent years, a wider understanding of the role of EBF1 in 
adipocytes has been reached. EBF1 was identified as a crucial player in insulin signaling 
where EBF1 loss in fat cells demonstrated a reduced insulin stimulated glucose uptake and 
lipogenesis. Inflammatory release of cytokines was also affected by EBF1 knockdown 
through toll-like receptors. Decreased EBF1 expression in mice results in WAT hypertrophy 
(42). Attenuated EBF1 activity and protein expression in human subcutaneous WAT 
(scWAT) is associated with several parameters of the metabolic syndrome (47). However, 
regulatory mechanisms of EBF1 activity are yet not defined. So far, only TNF-α has been 
suggested as an upstream regulator of EBF1 (42).  
1.4.3 Extracellular matrix composition  
Another crucial element in WAT remodeling is the extracellular matrix (ECM) (48). ECM 
builds up WAT architecture and contains structural proteins such as collagens in addition to 
adhesion proteins including fibronectin, laminin, elastin and proteoglycans. ECM is a non-
cellular portion of WAT surrounding the adipocyte like a web and the plasticity of ECM is 
believed to affect the morphology phenotype. It has been suggested that a relaxed ECM is 
better for a “healthy adipose tissue”, allowing adipocytes to grow and be dynamic upon 
nutritional changes. Conversely, an inflexible matrix would result in restricted adipocyte 
growth, ectopic fat accumulation and hence, increased risk of disease. The ECM homeostasis 
(balance between production and degradation) is disturbed in obesity and the damaging effect 
comes from increased synthesis of ECM components or impaired degradation resulting in 
fibrosis (49). There are currently two hypotheses on the chronological order of fibrosis and 
IR. The first suggests that WAT has a limited expansion capability and that fibrosis induces 
hypoxia which causes inflammation (50). The second theory proposes that WAT growth 
induces inflammation that in turn leads to fibrosis (51). Regardless of the order, a vicious 
cycle is created which contributes to an inflammatory condition.   
1.4.4 Vascularity  
Sufficient blood flow favors adipose tissue formation and the basis for this is angiogenesis. 
Although WAT is in general described as poorly vascularized when compared to other 
tissues, a dynamic vascular system is critical for WAT expansion and is considered to be rate 
limiting for WAT expansion (37). In addition, the obese state is associated with reduced 
supply of oxygen and density of vascularization, a condition termed hypoxia (52,53). 
Although recently, the first human study reported conflicting data, showing increased 
adipose tissue oxygen tension in obese compared with lean individuals (54). The theory 
behind this is that inadequate vascularization in adipose growth and/or increased adipocyte 
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size instead of number increases diffusion distances for oxygen. In hypoxia, there is an 
induction of the transcription factor (TF) hypoxia inducible factor 1 (HIF-1), which 
subsequently increases genes such as IL-6, vascular endothelial growth factor A (VEGFA), 
GLUT-1 and reduction of adiponectin (55). HIF-1 also induces ECM genes and indirectly 
influences fibrosis (50). Altogether, this suggests that hypoxia is involved in the pathogenesis 
of obesity by disrupting ECM homeostasis and inflammation response. This illustrates the 
complexity of WAT and its function.  
1.5 GENE REGULATION 
The central dogma of molecular biology postulates that genetic information is from DNA 
via mRNA to proteins. It is mechanistically quite well understood how genes are 
transcribed and how the mRNAs are translated into amino acid chains. Of course, gene 
regulation is much more complex than this three-step model and cellular function can be 
controlled at different levels involving numerous factors and post-translational events such 
as phosphorylation, methylation, acetylation, attachment of peptides, etc. The interaction 
among regulatory protein, transcription factors, RNA-molecules create complex regulatory 
networks. In addition a new set of post-transcriptional modifiers has been highlighted in the 
last decade termed microRNA (miRNA). They participate in almost every cellular process 
and are recognized as fine-tuning actors.  
1.5.1 MicroRNA 
MiRNAs are single stranded non-coding RNAs that belong to the RNA-interference class of 
regulators known to inhibit gene expression. In general, miRNAs are estimated to regulate up 
to 60 % of the genes in the human genome (56). A wide range of miRNAs have been 
reported to participate in obesity and the development of the metabolic syndrome. More 
specifically in adipocytes, miRNA are important for adipogenesis, fat cell development and 
regulation of the metabolic and endocrine function as reviewed (57). The expression of 
miRNAs is influenced by the state of health, and in obesity numerous miRNAs have been 
demonstrated to be dysregulated in adipose tissue and inflammation but also other tissues 
important for metabolism as reviewed (58). However, only a smaller part of expressed 
miRNAs have been verified experimentally in humans and even less detailed regulatory 
pathways have been described so far.  
1.5.1.1 Biogenesis of miRNA 
MiRNAs originate from the precursor molecules pri-miRNA, a double stranded RNA 
transcripts folded in a hairpin structure. The generation of miRNA is performed in two main 
steps. In the nucleus pri-miRNA is cropped to a 70-nucleotide (nt) pre-miRNA by the 
enzyme Droscha and further transported out to the cytosol. Here, pre-miRNA is cleaved by 
the enzyme Dicer to an approximately 20 nt miRNA duplex, one strand with 3' end and a 5' 
terminus strand. Generally, one strand is selected as mature miRNA whereas the other is 
degraded. Sometimes both strands of the duplex are used, functioning as mature miRNA. The 
single stranded miRNA is 18-23 nt of length and is fused together with ribonucleoprotein 
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from the Argonaute (AGO) family forming a complex named; miRNA-induced silencing 
complexes (miRISCs). Apart from the canonical miRNA biogenesis depicted in figure 1, 
there is also an alternative passage described which bypasses Droscha or Dicer processing 
(59). The miRISC guides the miRNA to the specific target by complementary binding to the 
3'-untranslated region (UTR) of target mRNAs. In the present thesis the research emphasis is 
on the systemic effect generated by miRNAs that is a squared area in figure 1.  
 
Figure 1. The canonical pathway of microRNA processing.  Source: Nat Cell Biol 11:228-34 (2009) (60). 
Printed with minor changes and with permission from the publisher.  
1.5.1.2 Silencing effects  
The interaction of base pairing of 2-8 nt needs to occur in the miRNA-mRNA association, 
also called seed region. The interface between miRNA and the gene enables the AGO-
proteins in the miRISC to repress the translation or induce mRNA degradation (61). The fate 
is determined by how well the miRNA binds to the target sequence, in other words, perfect or 
imperfect pairing results in various suppressions actions. Translational repression is mediated 
through imperfect base pairing. The exact mechanism is still not fully understood, yet data 
suggest that repression action occurs at initiation and elongation step (62–64). On the other 
hand, perfect base pairing causes in general mRNA disruption, the mechanistic feature differs 
between plants and animals (65). In animals, the removal of the poly (A) tail causes the 
mRNA strand to be more vulnerable for exonucleolytic degradation. In plants, the mRNA 
degradation is endonucleolytically cleaved by AGO (66). In contrast, there have also been 
indications that miRNA can activate translation although the mechanism is poorly 
described (67,68).  
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The effect of miRNAs on target genes can be executed in various ways, either directly or 
indirectly. The direct actions of miRNAs mean the interaction of the miRNA with the gene 
and thereby having repressive effect. Indirect involvement of miRNA allows the interaction 
of different components such as TFs, co-transcription factors and genes. Together, various 
signaling cascades creates a network with a few or several nodes (57). Identification of 
regulatory pathways is therefore a challenging task in the miRNA research. In figure 2 the 
different possible interplay between miRNAs and TFs are illustrated.  
 
Figure 2. The interplay between microRNA and transcription factors. Different types of regulatory networks 
involving miRNAs and TFs can be distinguished. (A) Transcription regulatory networks that consist of protein-
DNA interactions between TFs and the cis-regulatory DNA regions of their target genes (TF  target). (B) Post-
transcription regulatory networks that consist of RNA–RNA interactions between miRNAs and the 3'-UTR of 
their target mRNAs (miRNA  target). (C) Both types of networks can be combined into gene regulatory 
networks. Source: Bioessays. 2009;31:435-45 (69). Printed with minor changes and with permission from the 
publisher. 
1.5.1.3 Identification of miRNA targets  
There are a number of bioinformatics tools available to identify predicted targets of 
miRNA, the most common being miRanda, PicTar, PITA, TargetScan and RNA22. An 
extensive search can be performed on the platform miRWalk, which combines the 
information from separate database and miRNA target prediction programs (70,71). In 
general, the emphasis is on the miRNA-mRNA interaction 3'-UTRs, although emerging 
evidence imply the binding of 5'-UTRs, coding DNA sequence and/or non-coding RNAs 
(72). The 3'-UTR may contain multiple targeting sequences and other regulatory elements 
due to imperfect base pairing of miRNAs. Furthermore, one miRNA can bind a large 
number of genes and conversely one gene can be a target for multiple miRNA, see figure 2 
(69). To comprehend the functions of miRNA in complex biological processes, it is 
important to experimentally assess the functional relevance of the predicted targeting 
site(s). 
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2 HYPOTHESIS AND AIM  
2.1 GENERAL HYPOTHESIS AND AIM 
The overall hypothesis for this thesis is that miRNAs influences numerous factors regulating 
different aspects of adipocyte physiology thereby contributing to WAT dysfunction and 
development of IR. In four studies presented in the thesis, this has been investigated from 
different angles with the general aim to characterize dysregulated miRNAs in WAT, and link 
them to pathological pathways causing inflammation and IR.  
2.2 SPECIFIC AIM FOR THE STUDIES 
 
I. Extend and validate CCL2 regulatory network consiststing of obesity-dysregulated 
miRNAs and TFs in human adipocytes and macrophages.  
 
II. Determine if obesity-dysregulated miRNAs are involved in adiponectin regulation 
in human fat cells.  
 
III. Map expression of miRNAs associated with WAT morphology and their impact to 
EBF1 regulation. 
 
IV. Characterize miRNA expression profile in insulin resistant fat cells and elucidate 
their regulatory pathways affecting insulin signaling.  
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3 REMARKS ON THE METHODS  
In this section I, will give a brief introduction of the techniques used in this thesis and 
describe their strengths and weaknesses. A more detailed explanation of the methods is found 
in the corresponding papers.   
3.1 SUBJECT CHARACTERISITICS AND WHITE ADIPOSE TISSUE SAMPLES 
3.1.1 Cohorts 
Ethical approval was obtained for all studies and followed the statutes of The Declaration of 
Helsinki. All subjects included in the respective cohorts gave their informed written consent 
prior to participation. Three first studies are based on the same cohort, also referred to as 
cohort 1. Cohort 1 consists of 30 obese and 26 non-obese healthy women, see table 2 for 
clinical parameters (73). Study IV comprises 18 obese insulin-resistant (OIR), 21 obese 
insulin-sensitive (OIS) and 9 lean women, cohort 2. The characteristics of this group are 
described in detail in the paper.  
Table 2.  Clinical characteristics of Cohort 1 
  
Clinical Parameter 
 
Non-obese (n=26) 
 
Obese (n=30) 
   Age (years) 23-72           (43±14) 27-66              (43±10) 
   Weight (kg) 53.6-92.8     (67.6±8.5) 65.8-153.0      (111.9±22.1)  
BMI (kg/m
2
) 20.4-27.7     (24.2±1.8) 30.5-53.0        (41.0±6.8) 
Waist circumference (cm) 69.5-113.0   (85.2±9.2) 99.0-147.0      (121.7±13.9) 
Body fat (%) 22.5-38.9     (30.3±3.7) 41.0-73.3        (55.5±9.7) 
Fat cell volume (pL) 317.0-877.0 (501.6±153.8) 511.0-1349.0  (899.7±208.0) 
Total adipocyte number (10
10
 cells) 2.1-8.3          (4.8±1.5) 3.5-13.8          (7.9±2.6) 
Values are shown as range (mean ± standard deviation) 
3.1.2 White adipose tissue samples  
All subjects underwent a fine needle biopsy from subcutaneous abdominal WAT under local 
anesthesia. The adipocytes were isolated from the fat sample and the total number of 
adipocytes in the body was estimated, by dividing the total weight of body fat by mean 
adipocyte weight (15). The function of adipocytes is not disturbed by the biopsy procedure 
(74). 
3.1.2.1 Adipocyte morphology 
In study III, we compared the expression of miRNAs between hyperplasia and hypertrophy.  
In order to determine the morphology of the tissues, we used a curve fit relationship between 
adipocyte volume and the relationship between weight and length (BMI). The difference 
between observed and expected adipocyte volume obtained from the fitted curve reflects 
adipose morphology, where a positive value defines hypertrophy and a negative number 
hyperplasia (75).  
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3.1.3 Systemic insulin sensitivity 
Insulin sensitivity was determined by homeostasis model assessment of insulin resistance 
(HOMAIR). Fasting plasma insulin and glucose is measured and HOMAIR is calculated with 
following formula:   
HOMAIR  = Fasting plasma insulin (mU/L) * Fasting plasma glucose (mM/L) 
                    22. 5 
The cut off-value for IR was >2. This method is well established and frequently used and 
shows a good correlation with measures obtained using the golden standard hyperinsulinemic 
euglycemic clamp (76). 
3.2 CELL CULTURE SYSTEMS 
3.2.1  Primary cells 
In this thesis, almost all experimental data was generated in in vitro differentiated 
preadipocytes isolated from SVF of human WAT. This technique is well established and the 
cells have been characterized in detail before (77,78). The primary cultures display higher 
inter-individual variations compared to classical cell lines such as the murine 3T3-L1. This 
disadvantage can be avoided by using adipose derived stem cells (ASCs). They are obtained 
from one donor and are possible to expand through several passages. The common feature of 
ASCs and SVF-derived adipocytes is that they both have multiple lipid droplets. The most in 
vivo-like model is mature fat cells having one large fat droplet. The primary use of mature fat 
cell is for determination of adipokine secretion and assessment of lipogenesis. The main 
disadvantages with mature fat cells are that they float, fragile, difficult to handle and can only 
be kept in cultured medium for a maximum of a few days, thereby limiting the possibility of 
performing mechanistic studies.  
3.2.2 Immortalized cell line 
Immortalized cells were used as a complementary option to primary cells. The murine cell 
line 3T3-L1 was used for plasmid transfections, because it is an easier model system and 
well accepted cell-carriers for reporter assays.  These cells are convenient because they are 
robust, less sensitive than primary cells, expand quickly, cost-effective and overall easy to 
handle. On the other hand the drawback is that the cell cycle machinery has been 
manipulated and therefore the risk for spontaneous mutation is high. Every passage is also 
identical thus biological variation is low in addition to originating from another species. As 
mentioned in the papers, these cells were used for mechanistic experiment investigating if 
miRNA bind to the 3'-UTR sequence of a gene. Therefore the species differences might be 
of less importance, because we examined the physical binding.  
In paper I, THP1 cell line was used to study monocyte/macrophage cells, THP1 cells are 
derived from peripheral blood of a leukemia patient. Macrophages are flexible and assorted 
cells type. Depending on stimuli and tissue localization the differentiation mechanism will 
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vary and consequently trigger different polarization. In study I, the monocyte was 
differentiated with phorbol myristate acetate according to protocol into a non-polarized type 
(M0). This may not reflect their in vivo presence in WAT, and thus to get a more analogous 
environment co-culturing can be applied.  
3.3 DIFFERENCES IN SPECIES  
Within the metabolic research field it is highly appreciated to use animal models in order to 
implement specific functions in a complete and whole biological system. It is more common 
to study adipose tissue in mice, and subsequently follow-up in human samples, usually due to 
ethical reasons and difficulties of obtaining samples.  Although it might be more favorable to 
do the opposite e.g. first generating hypotheses based on human cohorts, then perform 
mechanistic studies in in vitro systems and verify in animal models. This is due to the inter-
species differences and the history of demonstrating pathological pathways in animals which 
has later been shown to be irrelevant in humans (79). The most obvious dissimilarity between 
human and rodents is the physiology and the distribution of brown adipose tissue and WAT. 
Human depots do not have a correspondence in rodents, e.g. the human visceral fat hardly 
exists in mice. Instead epididymal fat of male rats is used as a proxy for visceral fat (80). 
There is regional variation in the production of adipokines by adipose tissue in human vs. 
rodents. Several adipokines haves also been proven to exhibit contrasting roles. Adipsin and 
resistin are two examples, in addition to TNF-α that is not released into circulation as seen in 
mice (79,81). TNF-α is known to regulate adipocyte lipolysis although through different 
signaling pathways between species (82). There are also pathways for lipolysis regulation in 
humans that does not existing in rodents. Two examples of regulatory pathways found in only 
man is the α2 adrenergic receptor signaling negatively regulates lipolysis whereas natriuretic 
peptides are found to markedly increase lipolysis. There are also few examples of gene-
isoforms e.g. IRS-3 which undergoes tyrosine phosphorylation in rodent adipocytes but no 
functional gene or protein is found in humans (83). Another example is HSL, there are two 
isoforms in humans and one is unique displaying pathophysiological importance in insulin- 
resistant conditions, while only one form exists in mice (84). 
It is common to use obese models when performing research; the most recognized is leptin 
deficient mice (ob/ob) and disrupted leptin receptor mice (db/db). These mice represent an 
extreme state and leptin associated condition in humans is uncommon. Except for the 
obvious physiological differences between species this postulates why effects may differ 
between murine and human studies.  
3.4 MIRNA STRATEGIES 
3.4.1 Expression profiling 
The initial technical tool for this thesis is gene microarray, a methodology that enables 
global miRNA expression profiling. Results in papers I-III are based on the same array 
comparing the miRNA expression in WAT from lean and obese patients. For paper III, only 
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a subset of subjects were included and the array data was therefore reanalyzed based on the 
hypothesis. In study IV, we hypothesized altered miRNA expression between OIS and OIR 
and therefore an array was performed from cohort 2. The main advantages of microarray 
are the relatively low cost and small amount of RNA required without amplification. 
Microarray is a small chip containing several probes for each sequence of the genome but 
the discovery is limited by the annotated miRNAs on the chip. The workflow of the 
procedure starts with sample preparation implying isolation of RNA, conversion to cDNA 
and further the transcripts are labeled with fluorescent dyes. The sample material is put on 
the array for hybridization, washed and a laser registers light intensities. The emission is 
translated to expression of sequence by computational analyses and validation of the data is 
done by with real time quantitative polymerase chain reaction (RT-qPCR). Both the 
methods, microarrays and RT-qPCR, will reveal the relative difference in expression and 
not the absolute quantification. RNA-sequence is a more extensive technique, supplying 
with the absolute quantification and nowadays is considered as golden standard for 
translational profiling (85).  
3.4.2 Targets 
3.4.2.1 Bioinformatics approach 
Target identification of miRNA is usually a challenging work. Computational tools are 
extensively used and there are numerous commercial available databases, mentioned in 
section 1.6.1. The prediction is calculated with algorithms based on base- pairings between 
the miRNA and mRNA seed sequences, conservation among species and thermodynamic 
stability of the miRNA-mRNA interaction (86). Due to the great number of false-positives, 
functional validations are necessary in vitro and in vivo.   
3.4.2.2 Validation of targets 
Reporter assay in vitro was used to validate binding of miRNAs to its predicted mRNA 
targets and is an established method used to determine miRNA-mRNA interaction. In brief, 
the 3'-UTR sequence of target gene is inserted downstream of reporter gene in a DNA 
vector. We used dual Firefly/Renilla luciferase reporter that were obtained from Gene 
Copoeia. Activity of firefly luciferase is used for the detection of miRNA binding, e.g. 
when miRNA binds to its predicted target sequence, the luciferase activity is reduced and 
luminescence is decreased. Renilla luciferase gene in the same vector is used as an internal 
control for normalization of Firefly luciferase activity. Transfections were performed in 
murine 3T3- L1 cells using lipofection-based transfections agents as described in the 
papers. Light generated by Firefly and Renilla luciferases were detected 24 hours after co- 
transfection of reporter construct and relevant miRNA, mimic or miR-non-targeting control 
in 3T3-L1 cells. The method can determine the specificity of miRNA interaction site but will 
not specify where it binds exactly, however if the 3'-UTR sequence is mutated at the miRNA 
recognition site it can provide information about the binding site. Other ways to validate 
targets are based on the assumption of the interaction of miRNA and AGO protein forming 
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miRISC, as described in section 1.6.1.1. Techniques based on RNA immunoprecipitation will 
isolate miRISC by targeting AGO thereafter RT-qPCR or sequencing can be evaluated for 
determination of the binding (87–89),  
3.4.3 Functional analyses  
In all studies the hypothesis of miRNA action was functionally evaluated by modulating 
expression levels of miRNA in vitro. For induction of miRNA expression mimics reagents 
are used, these mimics naturally appearing miRNAs and are chemically manufactured 
double stranded oligonucleotides. To reduce the miRNA expression inhibitors products are 
used and they consist of single stranded RNA. Mimics/inhibitors are loaded to RISCs 
which are responsible for the action. The negative control are similar molecules but with no 
target. The main drawback with miRNA mimics or inhibitors are the off-target-effects. 
Therefore one needs to control the transfection by checking the miRNA expression, 
possible measure already known targets and preferable control that the miRNA binds to the 
gene of interest. Also, depending on the natural expression of the miRNA, when miRNA is 
highly expressed it’s more convenient to inhibit the expression and vice versa, if the 
miRNA is exhibiting low expression it is more rational to overexpress it. In the studies I-II 
results on both mimics and inhibition reagents are reported, e.g. miR-92a-3p (study I) and 
miR-193b-3p (study II). 
The pipeline after treating cells (independently of treatment) the samples were collected for 
RNA isolation, cDNA synthesis and assessment of mRNA expression using RT-cPCR to 
ensure effects of the overexpression, inhibition or gene silencing. The next step is to 
investigate if changes in mRNA levels can be detected on protein levels and this step is 
usually more problematic. Although mRNA levels will give an indication of protein 
changes, studies show that the correlation are with RT-qPCR and protein levels are quiet 
poor (90).  Therefore it is highly recommended to measure both mRNA and proteins if 
possible. The reason for low correspondence between mRNA and protein is mainly due to 
the complex features of proteins. Proteins vary in half time; post-translational modification, 
conformational folding and specific time-points can be crucial for detection of protein 
expression.  
3.4.3.1 Expression determination  
In this thesis, levels of miRNAs/mRNAs were determined using conventional methods such 
as RT-qPCR. For the expression quantification we amplified mRNA using Taqman and 
Sybro green assay. The principles of Taqman assays are that a specific probe is labelled 
with a fluorescent dye and quencher. The probe binds specifically to cDNA, which will be 
cleaved once the polymerase reaches the probe. Consequently, the releasing the flourophore 
from the probe and fluorescence will be emitted. The manufactures of the probes more are 
expensive compared to SYBR green assay. In this method the fluorescent DNA binding dye 
is non-specific and binds to all double-stranded DNA during elongation. Thus, there is a 
high rate of false-positive PCR-products and creation of primer-dimers.  SYBR green 
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primers need to be optimized before use by careful primer design and use of melting curves 
and gel. In both technologies a PCR apparatus detects fluorescense. In all experiments a 
reference gene was amplified in parallel, either 18S RNA or LRP10.  
3.4.3.2 Protein assessment  
For assessment of protein two conventional methods were used, Western blot and enzyme-
linked immunosorbent assay (ELISA). In both methods, a highly specific antibody is 
required. Western blot is considered to be a semi-quantitative method and the data provided 
gives a relative comparison of the protein levels and no measure of quantity is assessed. 
Western blot is an old and quite robust method, however it involves many steps and is time 
consuming and successful outcome is directly depend on the specificity of antibodies.  
3.4.3.2.1 ELISA 
ELISA is a quantitative method for the determination of the amount of any particular 
protein in a mixture. All the ELISAs used in the presented studies are commercially 
available and based on a sandwich enzyme immune assay. ELISA requires a low amount of 
sample and is simple to perform. The drawback of ELISA is highly dependent on antibody-
protein interaction, so if the binding would be unspecific this will not be verified. To avoid 
this, competitor ELISA can be used to detect the specificity of the antibody. The principle 
of competitor ELISA is that the sample antigen is incubated with the primary antibody for 
interaction. The complex is then added to wells coated with the same antigen. If the initial 
concentration of the antigen is high, there will be a smaller quantity to bind the primary 
antibody on the well, resulting in a reduced signal.  
In paper I-II, ELISA was used to assess amounts of secreted CCL2 and adiponectin proteins 
into conditional medium.  In study IV, ELISA was also used but here we used cell lysates 
for evaluate post-translational phosphorylation of the proteins involved in insulin signaling. 
3.4.3.2.2 Western blot 
For western blot we used whole or less complex nuclear lysate, described in the papers. The 
western blot includes three major steps. First the cells are lyzed in lysis buffer containing 
detergents and to solubilize the proteins. For nuclei preparation from adipocytes, cells were 
prepared based on swelling in hypotonic buffer, allowing disruption of cellular membrane 
but leaving nuclei intact. Nuclei are separated from cytosolic fraction by sedimentation 
followed by lysis generating soluble fraction of nuclear proteins. The proteins are separated 
by SDS-PAGE by size and transferred to a membrane followed by Western blot 
procedures. Specifically, the unspecific sites on membrane are blocked using various 
blocking agents such as BSA or non-fat milk followed by incubation with primary and 
secondary antibodies of interest.  The antigen-antibody complexes are detected using 
chemiluminiscence, the intensity of the bands are evaluated by densitometry and the 
relative levels of proteins are calculated in relation to loading control proteins such as actin 
of lamin A/C.  
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3.4.3.3 Insulin signaling  
In manuscript IV, we studied insulin sensitivity in fat cells and evaluated ability of cells to 
incorporate triated glucose into lipids. Total glucose uptake into lipids was also performed 
in in vitro differentiated adipocytes with modulated levels of miRNA. The rationale behind 
the use of glucose is that it is incorporated into lipid and rate limiting for lipogenesis. This 
is a well-established method and for a more detailed description see (91,92).    
 28 
4 RESULTS AND DISCUSSION 
In this section, the most remarkable findings are summarized and discussed, a complete 
description of the results is found in each respective paper. Studies I-III are follow-up 
projects from our lab, with the same patient cohort, but with novel individual hypothesis. The 
study by Arner et al. was among the first to investigate obesity-dysregulated miRNAs and 
their link to inflammation (73). In there, gene and miRNA expression were profiled in 
scWAT obtained from 56 subjects (cohort 1). Adipocyte-specific transcription regulatory 
network (TRN) controlling CCL2 expression in obesity was constructed based on the altered 
expression of miRNAs and altered activity of TFs in obese vs. non-obese, later determined by 
Motif activity response analysis (MARA) (73). Briefly, MARA is a method developed to find 
key regulatory elements that identify active promoters and align them with defined motifs 
followed by calculation of motif activity (93). Therein, 11 miRNAs were discovered to be 
significantly dysregulated in obesity, affecting CCL2 production directly or indirectly 
through TFs (73). 
In study I, the TRN regulating CCL2 was extended and validated. Interacting circuits of 
miRNAs and TFs were further verified in human adipocytes and macrophages. In study II, 
we investigated if the obesity-dysregulated miRNAs affected adiponectin production in 
human adipocytes. For study III, we aimed to discover miRNAs associated with differences 
in WAT morphology. In the fourth study we intended to identify miRNAs involved in the 
development of fat cell insulin sensitivity. An overview of the presented studies in this thesis 
is illustrated in figure 3.  
 
Figure 3. An outline of the study strategies presented in this thesis.  
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4.1 STUDY I  
As mentioned above, study I is based on previous investigations from our lab, defining 
miRNAs possible role in controlling CCL2 production (73). By using a systematic unbiased 
approach, 10 miRNAs were demonstrated to affect CCL2 production, and for two of them 
(miR-126-3p and -193b-3p) the direct or indirect regulatory circuits were defined. For the 
first study, we extended and validated the above described miRNA network. We used gain-
off-function/loss-of-function techniques to examine the impact of TFs and miRNAs on 
CCL2 expression in human adipocyte and macrophages. We focused on a part of the TRN 
investigating the regulatory pathway of miR-92a-3p which was not fully characterized in 
the previous study. Firstly, we investigated if miR-92a-3p affected its predicted target, 
specificity protein 1 (SP1) and v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 
(ETS1).  Alteration of miR-92a expression affected mRNA and protein expression of SP1 
but not ETS1 and miR-92a-3p interacted directly with the 3'-UTR region of SP1. SP1 alone 
regulated CCL2 production as evidenced by decreased CCL2 production after silencing of 
SP1 and reduced expression of v-rel reticuloendotheliosis viral oncogene homolog (avian) 
(REL), which is a part of the nuclear factor (NF)-κB family.  
In the previous study, miR-193b-3p was shown to regulate CCL2 through ETS1 and MYC-
associated factor X (MAX) (73).  We wanted to evaluate if these TFs could affect CCL2 
without the impact of miR-193b-3p. ETS1 knock down decreased mRNA levels of MAX, 
signal transducer and activator of transcription 6, interleukin-4 induced, nuclear factor of k 
light polypeptide gene enhancer in B-cells 1, and CCL2. Silencing the expression of MAX 
diminished the mRNA levels of RELB. The findings lead us to hypothesize that the TFs 
might have synergistic effects on the CCL2 production, which were confirmed by co-knock 
down of ETS1 and MAX.  
These observations indicate that miRNAs have combinatorial properties by amplifying the 
effects of each other (94). Therefore, we tested the effects of co-overexpressing the miRNAs 
involved in the studied TRN (miR-193b-3p, -126-3p and -92a-3p) in both adipocytes and 
macrophages. We found that two combinations of miRNAs (miR-193b-3p + 92a-3p and 
miR-126-3p-3p + 92a-3p) reduced CCL2 expression, while no effect was observed for miR-
126-3p + 193b-3p in adipocytes.  On the contrary, only a combination of miR-126-3p + 
193b-3p had effect on CCL2 production in macrophages.  
Taken together, the novelty of this study is that the regulatory interactions between miRNAs, 
and TFs were determined in different cell types e.g. adipocytes and macrophages, shown in 
Figure 4. Understanding the miRNAs individual function as well as the interaction with other 
miRNAs, exhibiting synergistic effects, is key in order to get an overview of the regulation. 
We studied two levels of regulation including TFs and miRNAs, however the TRN could be 
extended, including more levels of regulation such as methylation and phosphorylation. A 
more comprehensive investigation to determine the mechanistic crosstalk between 
macrophages and adipocytes is one more possibility to extend the study. Here we examined 
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only scWAT obtained from female donors and further studies can be addressed to find 
possible sex- and region- specific differences in the regulation of CCL2 production. 
 
Figure 4. miRNA regulatory circuits that control levels of CCL2 in human white adipose tissue. Transcription 
factors (ETS1, MAX, SP1 and an NF-κB subnetwork) and miRNAs (miR-92a-3p, miR-126-3p and miR-193b-
3p) are integrated in a regulatory network of CCL2. The experimentally verified network demonstrates that 
miRNAs regulate CCL2 in additive manner. In adipocytes, two combinations was identified; miR-92a-3p + 
miR-193b-3p acts through a transcriptional regulatory network to control CCL2 (A1); miR-126-3p acts directly 
on CCL2 but also together with miR-92a-3p through transcription factors (A2). The transcription factors ETS1 
and MAX demonstrate synergistic effects in their control of CCL2 (A3). In macrophages, miRNAs could act 
directly or indirectly regulating CCL2. T bars indicate inhibition; arrows indicate stimulation. Bold lines 
represent interactions between network players in adipocytes and thin lines are interactions predicted by network 
analyses and/or shown in other cell types. Dashed lines in the lower part represent possible interactions. The 
networks presented do not include transcription factors without known DNA-binding motifs and co-regulators of 
transcription factors. Source: Nat Rev Endocrinol. 2015;11:276-88 (57). Printed with minor changes and with 
permission from the publisher. 
4.2 STUDY II 
The beneficial metabolic effects of adiponectin have been intensively investigated although 
the molecular mechanisms regulating the expression of this adipokine are not well mapped. 
In specific, there are not much data available on adiponectin regulation by miRNAs. 
Therefore the objective of study II was to determine whether adipocyte-expressed miRNAs 
altered by obesity can regulate adiponectin expression/secretion in fat cells. Eleven miRNAs 
previously shown to be dysregulated in obese human WAT were overexpressed in human in 
vitro differentiated adipocytes followed by assessments of adiponectin levels in conditioned 
media.  
Three miRNAs (miR-193b-3p/ -126-3p/ -26a-5p) increased the adiponectin levels in 
conditioned medium. However, only miR-193b-3p demonstrated clinical relevance as its 
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expression correlated with adiponectin gene expression and measures of insulin resistance 
(HOMAIR) in the clinical cohort of 56 subjects. In general, miRNAs down-regulate their 
predicted targets. As we found that miR-193b-3p overexpression up-regulated adiponectin 
secretion indicated that the mechanisms linking the miRNA to adiponectin were indirect. 
Moreover, the effects are probably via upstream negative regulators (e.g. 
miRNAintermediate regulatorADIPOQ). Our hypothesis was supported by 
bioinformatics analyses, in which ADIPOQ was not a direct target of miR-193b-3p. This 
prompted us to search for predicted miR-193b-3p targets among genes known to affect 
adiponectin production. We identified 11 negative regulators of adiponectin that were also 
predicted miRNA-193b-3p targets. Even though the adiponectin-regulating genes were 
predicted targets of miR-193b-3p, they were not validated experimentally. Therefore, we 
measured the mRNA expression of the genes (adiponectin regulators) in adipocytes with 
altered levels of miR-193b-3p. Overexpression of miR-193b-3p decreased the abundance of 
cAMP-responsive element binding protein 5 (CREB5), nuclear transcription factor Y α (NF-
YA), nuclear receptor interacting protein 1 (NRIP1), protein kinase D3 and retinoid X 
receptor-α, suggesting that the genes are potential targets of miR-193b-3p. However, 3'-UTR 
reporter analysis confirmed that only CREB5, NF-YA and NRIP1 were direct targets of miR-
193b-3p. 
The effect of miR-193b-3p on NF-YA was confirmed at the protein level whereas CREB5 
protein, in contrast to the findings at the mRNA level, was increased. All tested primary 
antibodies detecting NRIP1 were unspecific in human adipocytes and therefore data cannot 
be demonstrated. To strengthen the mechanistic part of evidence, we studied the interaction 
of miR-193b-3p with NF-YA and NRIP1 by co-transfecting in vitro differentiated 
adipocytes with miRNA mimics and target protectors corresponding to the binding site of 
miR-193b-3p on the 3'-UTR of NF-YA or NRIP1 followed by the evaluation of adiponectin 
secretion. Target protectors are small RNA molecules specific for a single target gene and 
miRNA. They specifically interfere with the interaction between a miRNA and its target 
sequence. Indeed, co-transfection of the target protectors eliminated the effect of miR-193b-
3p on adiponectin production 
. 
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Figure 5. The suggested regulatory role of adiponectin by miRNA in human fat cells. The pathway of miR-
193b-3p towards adiponectin regulation was experimentally verified, indicating that NF-YA is and possibly 
NRIP1 are the intermediate players directly targeted by miR-193b-3p.  
Research in the adiponectin field includes the regulation of miRNAs by adiponectin or the 
regulation of adiponectin receptor expression by miRNAs (95–99).  Our findings contribute 
with a novel regulatory layer, specifically the regulation of adiponectin by miRNA in 
human adipocytes and are illustrated in figure 5. Altogether, the results recognize a 
clinically relevant miR-193b-3p that is downregulated in obesity and controls adiponectin 
expression through binding of NF-YA and probably NRIP1.  
4.3 STUDY III (MANUSCRIPT) 
WAT morphology characterized by hypertrophy associates with increased adipose 
inflammation, lipolysis, insulin resistance, and risk of diabetes. However, the causal 
relationships and mechanisms controlling WAT morphology are unclear. Our group recently 
identified EBF1 as an adipocyte expressed TF with decreased expression/activity in WAT 
hypertrophy (42). In human adipocytes, the regulatory targets of EBF1 were enriched for 
genes controlling lipolysis and adipocyte morphology/differentiation and reduced EBF1 
levels were associated with increased lipolysis and adipose hypertrophy. However, the 
mechanisms controlling EBF1 expression are not known, neither any miRNAs linked to 
human WAT morphology have been identified. Therefore, we aimed to identify miRNAs 
associated with differences in WAT morphology and determined whether they could affect 
the expression of EBF1.  
With this aim we analyzed previously published miRNA expression data from 26 non-obese 
individuals subdivided into hypertrophy (n=13) or hyperplasia (n=13) (42,100). We focused 
on the miRNA expression in lean individuals due to the fact that fat cell morphology is more 
evident in lean than obese.  The analysis allowed us to identify 15 differentially regulated 
miRNAs (miR-574-5p, -361-5p, -143-3p, -222-3p, -221-3p, -125b-5p, -106a-5p, -26a-3p, -
23a-3p, -16-5p, -17-5p, let-7a, -7c-5p, -7d and -7i-5p), all of which were significantly highly 
expressed in hypertrophy. Interestingly, ten miRNAs (let-7a, -7c-5p, -7d, -7i-5p and miR-
106-5p, -143-3p, -221-3p, -23a-3p, -361-5p and -574-5p) were predicted to target EBF1. This 
finding prompted us to perform 3'-UTR analysis of EBF1 and above mentioned miRNAs. 
Overexpression of miR-361-5p and -574-5p caused a significant downregulation of luciferase 
reporter activity, indicating that EBF1 is a true target for these miRNAs in adipocytes. For 
functional studies of the miR-361-5p and -574-5p, we overexpressed each miRNAs 
independently which consequently reduced EBF1 levels by 15-24 %. We also tested if the 
miRNAs (miR-361-5p and 574-5p) could possess additive effects on EBF1 regulation. 
Indeed, co-transfection of both miR-361-5p and -574-5p using low concentrations of mimic 
reagents resulted in a more pronounced reduction of EBF1 expression (~15 %) compared 
with individual overexpression of either miRNAs.  
We tested if overexpression of miRNAs reduced proteins levels of EBF1. However, at this 
point, we could not detect the same amount of EBF1 protein reduction as was detected on 
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mRNA levels. The lack of difference in EBF1 protein levels could depend on low affinity 
and/or specificity of primary antibodies used. Another explanation could be long half-life of 
EBF1 protein. Previous study by Rosen et al. demonstrated that EBF1 has a half time of 
seven days (101). Since EBF1 is also an important factor for adipogenesis, it is not reasonable 
to manipulate levels of EBF1 at early stages of differentiation due to possible anti-
adipogenenic effects. To overcome the limitations we are currently investigating other ways 
to quantify EBF1 protein levels, testing new antibodies and investigating if the protein 
changes could be more profound in the nuclear lysates instead of total cell lysate. 
In the previous study by Gao et al. the factor Cell Death-Inducing DFFA-Like Effector A 
(CIDEA) was regulated by EBF1 (42). CIDEA is known to be exclusively expressed in 
human WAT and  an important metabolic factor, controlling lipolysis and TNF-α secretion 
(102). We therefore hypothesized that CIDEA could possibly be altered as a secondary effect 
of the studied miRNAs. Indeed, CIDEA mRNA levels were reduced by overexpression of 
miR-361-5p and -574-5p.  Because EBF1 is a transcription factor and its expression is altered 
in obesity, its activity was determined by MARA in the previous study (73). We used the data 
to perform an association analysis that revealed significant and negative correlation with the 
expression of both miRNAs in fat cells independently of BMI.  
In summary, we identified miR-365-5p and -574-5p that could be linked to WAT 
hypertrophy and their potential role in regulating fat cell morphology due to their attenuating 
effects on EBF1 expression (Figure 6). These miRNAs could therefore have a 
pathophysiological relevance and play an important role for the development of insulin 
resistance. An overview of the obesity dysregulated miRNAs in WAT recently obtained by 
co-workers of our group is summarized in table 3.  
 
Figure 6. Proposed pathway of EBF1 regulation by miR-361-5p and -574-5p in hypertrophic human WAT. Both 
miR-361-5p and -574-5p bind and thereby regulate EBF1 independently and in an additive manner. 
4.4 STUDY IV (MANUSCRIPT) 
In this study we aimed to gain insight into the regulation of fat cell insulin sensitivity by 
miRNAs.  So far there is only a handful of studies of miRNAs in relation to IR of human fat 
cell (103,104). We selected obese individuals based on insulin sensitivity that was determined 
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by insulin-stimulated minus basal lipogenesis of isolated fat cells. This way we could 
generate the cohort consisting of 21 OIS, 18 OIR and 9 lean subjects as controls. The obese 
groups were matched for BMI, waist circumference and fat cell size, all of which may 
influence insulin sensitivity independently of lipogenesis values. More clinical data could be 
found below in the manuscript of study IV.  
A combination of global miRNA measurements and validations of miRNA expression with 
RT-qPCR identified eleven adipose miRNAs to be differently regulated in IOS compared to 
IOR. These candidate miRNAs were further pursued for functional studies in vitro. The 
miRNAs were overexpressed in human differentiated adipocytes followed by measurements 
of basal and insulin-stimulated glucose incorporation of lipids. Two miRNAs (miR-143-3p 
and miR-652-3p) increased glucose incorporation into lipids in response to insulin.  
The possible clinical impact was evaluated by performing association analysis of the 
miRNAs expression determined by RT-qPCR in intact WAT with the lipogenesis values in 
isolated fat cells ex vivo. Indeed, expression of both miR-143-3p and miR-652-3p correlated 
to insulin-stimulated lipogenesis independently of BMI. To identify targets of miR-143-3p 
and miR-652-3p involved in lipogenic pathways and to delineate their possible regulatory 
pathways, we selected for known genes involved in insulin signaling, insulin 
sensitivity/resistance and lipogenesis. To identify if these genes could possibly be targeted by 
the miRNAs, they were overlapped with the list of predicted targets of the miR-143-3p and 
miR-652-3p. We identified 13 and 8 genes for miR-143-3p and miR-652-3p respectively 
thus, mRNA expression was measured after overexpression of the miRNAs in adipocytes. 
Overexpression of miR-143-3p increased PRKAA1 mRNA levels by about 35 % while 
overexpression of miR-652-3p downregulated ENPP1 by 30 %. The findings were also 
confirmed at the protein levels for both genes. As miR-652-3p reduced its predicted target, 
one could suspect that it directly targeted ENPP1. Indeed, the direct binding of miRNA- 652-
3p to the 3'-UTR of ENPP1 was confirmed by the luciferase reporter assay.  
As mentioned in section 1.3.1.1, insulin signaling comprises of numerous phosphorylation 
events and the protein kinase AMPK is an important regulator for energy metabolism 
responsible for direct phosphorylation of metabolic enzymes. PRKAA2 is a catalytic subunit 
of AMPK. The fact that overexpression of miRNA-143-3p increased expression of PRKAA2 
allowed us to hypothesize for indirect effects where posttranslational events could be 
involved. Obviously, miRNA-652-3p also targets multiple targets, many of them indirectly. 
Thus we overexpressed both miRNAs in adipocytes, and measured total and phospho-
proteins at the activating residues of the main insulin signaling players using ELISA (Akt2, 
phospho-Akt2, total IRS-1, phospho-IRS1, Insulin Receptor β and phospho-Insulin Receptor 
β). We found that phosphorylation of AKT2 at Ser474-site was induced by miR-143-3p and 
miR-652-3p increased phosphorylation of AMPK at activating residue Thr172 and total 
phosphorylation of IRS-1. 
In summary, miR-143-3p and miR-652-3p were downregulated in OIR compared to OIS 
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women. We found that they increase insulin-stimulated lipogenesis directly by reducing 
ENPP1 and indirectly by inducing post-translational (PRKAA2) and phosphorylation’s 
events. The main findings are illustrated in a schematic picture (Figure 7).  
 
Figure 7. A schematic summarization of miRNAs involved in glucose incorporation in human white 
adipocytes. Two miRNAs was found to be downregulated in obese insulin resistant adipose tissue and suggested 
to regulate lipid incorporation. The circuit of the experimentally validated miRNAs indicated that miR-143-3p 
indirectly affects PRKAA2 (indicated by dashed line), whereas miR-652-3p was found to bind and regulate 
ENPP1. Both miRNAs was moreover engaged in phosphorylating important insulin signaling factors such as 
AKT2, AMPK and IRS-1 through undefined mechanism.  
Here, we included phosphorylation events that positively regulate insulin signaling due to the 
stimulatory effects of the miRNAs on glucose incorporation to the lipids. Phosphorylation of 
residues promoting inhibitory effects is also important but was not covered in here. It would 
be interesting to more thoroughly investigate and characterize miRNAs effect on insulin 
signaling post-translationally and especially the phosphorylation actions.  
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           Table 3.  An overview of the obesity dysregulated miRNAs in WAT and their effect on adipocyte function. 
MicroRNA 
  
Expression in WAT Combinatorial effect 
 
Affect 
Effect 
on  Lipolysis Obese/lean IS/IR Morphology CCL2 Adiponectin TNF- α 
Let-7a-5p down - - - yes no Yes no 
Let-7d-5p down - up in hypertrophy - yes no yes yes 
miR-26a-5p down down up in hypertrophy - yes yes yes yes 
miR -30c-5p down - - - no no no yes 
miR -92a-3p down - - 
on CCL2 (miR-
92a+193b/126) 
yes no yes no 
miR -126-3p down - - on CCL2 (miR-126+92a) yes yes no no 
miR -143-3p down down up in hypertrophy - yes no yes no 
miR-145-5p down down - - yes no yes yes 
miR-193a-5p down - - - yes no yes no 
miR-193b-3p down - - on CCL2 (miR-92a+193b) yes yes yes yes 
miR-652-3p down down - - yes no no yes 
miR-361-5p - - up in hypertrophy on EBF1 (miR-361+574) - - - - 
miR-574-5p - - up in hypertrophy on EBF1 (miR-361+574) - - - - 
References 
 
Arner et al. 
(2012) (73) 
 
Dahlman 
et al. (MS) 
 
Belarbi et al. (Manuscript          
2016) 
 
Kulyté et al. (2014) (105), 
 Belarbi et al. (Manuscript 2016) 
 
Kulyté et al. 
(2014) (105) 
 
Belarbi et al. 
(2015) 
 
Lorente-
Cebrian et al. 
(2014) (106) 
 
Lorente-Cebrian et 
al. (2014) (106) 
 
            Abbreviations: IS, insulin sensitive; IR, insulin resistance; CCL2, chemokine (C-C Motif) Ligand 2; TNF- α, tumor necrosis factor α; EBF1, early B cell factor 1.  
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5 CONCLUSION AND FUTURE PERSPECTIVES 
WAT has a remarkable ability to adapt and remodel in response to under- and over nutrition.  
The flexibility of WAT includes alterations in the structure and composition that 
consequently affects adipocyte metabolism. The biology of the different conditions of WAT 
is complex and extensive research is performed in order to understand the molecular events 
and its clinical impact. The focus of this thesis was to identify miRNAs in WAT and map 
their regulatory pathways in relation to obesity and IR. Our results provide novel insights on 
the function of miRNAs in human adipocytes. Nevertheless, many questions remain to be 
addressed.  
Future investigations are needed to evaluate the clinical impact of the dysregulated 
miRNAs and to elucidate the complete gene regulatory networks in WAT and their 
contribution to insulin sensitivity and inflammation. For all four studies, the experimental 
pipeline was to identify miRNAs by global expression analysis of the miRNA transcriptome. 
Further finding and validating comprehensive pathways leading to clinical pathologies is 
even more important. Studies I-III are based on the same cohort (cohort 1) consisting of lean 
and obese individuals, where expression analysis of miRNA and genes were assessed.  Data 
revealed that 11 miRNAs were dysregulated in obesity (73). We further studied miRNAs and 
miRNA-gene regulatory networks to get insights into different aspects of WAT function, e.g. 
inflammation (studies on CCL2 and adiponectin) and WAT morphology (EBF1 study). In 
study IV, we evaluated the impact of miRNAs on insulin sensitivity in obese subjects. 
Altogether, these studies demonstrate the impact of miRNAs in regulating WAT function.   
A further apparent and very relevant investigation is to create networks that include 
additional levels of regulation including chromatin marks (DNA methylation, histone 
modifications) and post-translational modifications such as phosphorylation and methylations 
events.  In addition, it would be of interest to map the obesity-regulated miRNAs which were 
excluded from more detailed analyses due to various reasons.  By including these miRNAs, 
the regulatory network could be extended. For example in study III it would be interesting to 
study the remaining 9 miRNAs, and how they may be involved in regulating WAT 
morphology through e.g. EBF1, PPARG, and C/EBPα. These three genes encode TFs that 
cross talk and regulate each other and all are downregulated in hypertrophic non-obese WAT 
(42,101). In general, studies on the regulation of miRNAs themselves are lacking and it 
would be highly relevant to consider this extra layer. Other aspects of interest are the ability 
of miRNAs to act in a combinatorial manner and to characterize if/how miRNAs crosstalk 
with other tissues e.g. through exosome secretion.  
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